Actively Recruiting
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Led by Sun Yat-sen University · Updated on 2025-02-06
300
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC). However, the evidence for infiltrative is limited. In this study, we aimed to describe the efficacy and safety of lenvatinib and PD-1 inhibitor with HAIC plus lenvatinib for infiltrative HCC.
CONDITIONS
Official Title
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Primary infiltrative hepatocellular carcinoma confirmed by MRI or CT imaging
- Child-Pugh class A or B liver function
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Lenvatinib used as initial treatment
- Patients receiving HAIC plus lenvatinib and PD-1 inhibitor, or lenvatinib alone
- No history of other cancers
- No tumor thrombus in the atrium or vena cava
You will not qualify if you...
- Hepatocellular carcinoma with tumor capsule
- Younger than 18 years or older than 75 years
- Transarterial chemoembolization (TACE) as initial treatment
- Use of sorafenib or other systemic therapy with or without PD-1 inhibitor after HAIC
- Incomplete tumor imaging data
- Lost to follow-up within three months after treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
Q
Qunfang Zhou, MD
CONTACT
F
Feng Duan, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here